Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus
Authors:
- Devada Singh-FrancoDSDevada Singh-Franco
- Gisela RoblesGRGisela Robles
- David GazzeDGDavid Gazze
- 1 April 2007
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 29 (4) , 535-562
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2004
- Global Prevalence of DiabetesDiabetes Care, 2004
- Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjectsEuropean Journal of Clinical Investigation, 2003
- Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrationsDiabetologia, 2001
- Adrenomedullin and related peptides: receptors and accessory proteinsPeptides, 2001
- Lack of Suppression of Glucagon Contributes to Postprandial Hyperglycemia in Subjects with Type 2 Diabetes MellitusThe Journal of Clinical Endocrinology & Metabolism, 2000
- Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance.Diabetes Care, 2000
- High-frequency oscillations in circulating amylin concentrations in healthy humansAmerican Journal of Physiology-Endocrinology and Metabolism, 2000
- Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humansDiabetologia, 1991
- Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.Journal of Clinical Investigation, 1984